Surgery alone
Sponsors
Taiho Pharmaceutical Co., Ltd., University Health Network, Toronto, Catrine Isehed, North Tees and Hartlepool NHS Foundation Trust, Tata Memorial Hospital
Conditions
Bacterial InfectionsBleeding of Subgingival SpaceBreast CancerCancerColorectal CancerFailure of Dental Implant Due to InfectionGastric CancerHCC - Hepatocellular Carcinoma
Phase 2
Phase 3
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)
CompletedNCT00152243
Start: 1997-06-30End: 2007-08-31Target: 500Updated: 2011-07-07
A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)
CompletedNCT00152230
Start: 1996-10-31End: 2008-02-29Target: 900Updated: 2011-07-07
Phase 4
Unknown Phase
Femoral Bone Metastases
Active, not recruitingNCT01428895
Start: 2009-03-01End: 2027-02-01Target: 180Updated: 2026-03-06
Investigating the Use of Drains and (Internal) Quilting Sutures on Seroma Formation Following Mastectomy
NCT02668263
Start: 2015-11-30End: 2016-11-30Target: 120Updated: 2016-01-29
To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.
Active, not recruitingNCT03669432
Start: 2013-07-31End: 2026-07-31Updated: 2022-05-02
Neo-TACE-HAIC for PVTT-HCC
NCT04181931
Start: 2019-12-16End: 2024-12-30Target: 320Updated: 2020-10-26
Neo-TACE-HAIC for BCLC B Stage HCC
NCT04424043
Start: 2020-07-08End: 2025-12-30Target: 280Updated: 2020-10-26
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
RecruitingNCT04777942
Start: 2021-02-20End: 2026-12-30Target: 320Updated: 2021-03-02
Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization
RecruitingNCT05327933
Start: 2022-05-26End: 2025-10-31Target: 154Updated: 2025-03-30
Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)
Not yet recruitingNCT07383142
Start: 2026-02-01End: 2032-02-01Target: 202Updated: 2026-02-06
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Not yet recruitingNCT07618546
Start: 2026-05-25End: 2028-03-31Target: 208Updated: 2026-06-01